RNLXY — Renalytix plc
—
OTC ·
Health Care ·
Health Care Providers & Services ·
CIK 1811115 ·
United Kingdom
Last close
$4.00
Market Cap
$48.31M
52W High
$175.00
52W Low
$1.00
ADV30
3,107
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 9,900,000 | 6,100,000 | 11,100,000 |
| Dec 2024 | 729,000 | 398,000 | -3,396,000 | -3,882,000 | 11,441,000 | 9,209,000 | 12,810,000 |
| Sep 2024 | 522,000 | 100,000 | -4,092,000 | -4,728,000 | 4,794,000 | 909,000 | 16,113,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,497,000
Investing CF
$-1,000
Financing CF
$15,035,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-173,400,000
Inventory
$300,000
Receivables
—
ST Investments
$100,000
EBIT TTM
$-4,418,000
Pretax Income TTM
$-3,884,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,300,000
EBITDA
—
Free Cash Flow
—
Enterprise Value
$36,309,568
Total Cash
$6,200,000
Total Debt
$5,800,000
Shares Out
12,076,614
Trailing EPS
$-2.00
Book Value
$-0.15
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 3,000,000 | -17,200,000 | -20,400,000 | 6,100,000 | 13,100,000 | -7,000,000 | -17,900,000 |
| Jun 2024 | 2,300,000 | -30,500,000 | -45,500,000 | 7,100,000 | 16,100,000 | -9,000,000 | -29,800,000 |
| Jun 2023 | 3,403,000 | -42,221,000 | -45,607,000 | 30,629,000 | 23,662,000 | 6,967,000 | -34,085,000 |
| Jun 2022 | 2,970,000 | -53,183,000 | -45,276,000 | 50,065,000 | 19,458,000 | 30,607,000 | -45,924,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EUDA | EUDA Health Holdings Ltd | $53.48M | $17.86 | — |
| MDXH | MDxHealth SA | $53.91M | $0.56 | — |
| RENXF | Renalytix plc | $39.85M | $0.07 | — |
| ALPS | Alps Group Inc | $65.89M | $0.40 | — |
| CCEL | CRYO CELL INTERNATIONAL INC | $34.19M | $4.24 | — |
News headlines (Yahoo Finance, 1h cache)
KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists
2026-06-30 11:43 · Yahoo
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
2026-05-12 11:43 · Yahoo
Renalytix rises 7% as UBS holding grows and CEO buys shares
2026-09-11 09:45 · Yahoo
Renalytix shares surge 19% as trading resumes after cash call
2026-09-08 08:30 · Yahoo
Quest’s Expanded Alzheimer’s and Wellness Testing Push Might Change The Case For Investing In DGX
2026-09-04 05:09 · Yahoo
Carna Health Taps Multidisciplinary Healthcare and Technology Experts to Guide the Future of Cardio-Kidney-Metabolic Care
2026-08-27 13:18 · Yahoo
Renalytix shares climb 24% as two-year kidney study data published
2026-06-30 08:52 · Yahoo
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
2025-11-18 12:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.